Chardan Capital Reiterates Buy on Arrowhead Pharma, Maintains $60 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Keay Nakae reiterated a Buy rating on Arrowhead Pharma (NASDAQ:ARWR) and maintained a $60 price target.
May 24, 2023 | 8:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital's Keay Nakae reiterated a Buy rating on Arrowhead Pharma (ARWR) and maintained a $60 price target.
The reiteration of a Buy rating and maintenance of a $60 price target by Chardan Capital's analyst Keay Nakae indicates a positive outlook for Arrowhead Pharma's stock. This news is likely to have a positive impact on ARWR's stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100